Treatment with the TβRII inhibitor LY2109761 also rescued the effect of HTR1A knockdown on TβRII/p‐Smad3 expression and the migration ability of breast cancer cells (Figure 3e–g). Here, TGFBR2 is linked to breast carcinoma.